Cobimetinib + vemurafenib recipients with SR (n = 63) | Placebo + vemurafenib recipients with SR (n = 7) | Overall coBRIM population (N = 493) | |
---|---|---|---|
Age, years | |||
Median | 59 | 62 | 55 |
Range | 30–78 | 33–76 | 23–88 |
Sex, n (%) | |||
Male | 37 (58.7) | 2 (28.6) | 286 (57.8) |
Female | 26 (41.3) | 5 (71.4) | 209 (42.2) |
Region, n (%) | |||
Europe | 51 (80.9) | 5 (71.4) | 366 (73.9) |
Australia/New Zealand | 8 (12.7) | 2 (28.6) | 78 (15.8) |
North America | 4 (6.4) | 0 | 51 (10.3) |